Compare Abbott Laboratories (ABT) vs Nokia Corp (NOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Nokia Corp — how do they compare? Abbott Laboratories trades at $109.32 (market cap $187.95B), while Nokia Corp trades at $10.35 (market cap $53.00B). The key difference: Abbott Laboratories is far larger — about 3.5× Nokia Corp's market cap, and Abbott Laboratories pays the higher dividend (2.32%). Which is the better fit depends on your goals.
| ABT | NOK | |
|---|---|---|
Market Cap | $187.95B | $53.00B |
Sector | Health | Technology |
52-Week High | $136.62 | $16.83 |
52-Week Low | $82.57 | $4.13 |
Enterprise Value | $214.96B | $50.95B |
Dividend Yield | 2.32% | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Nokia (NOK) trades at $9.12, down 2.67% today amid a bearish technical signal, with mixed earnings performance including a Q2 2026 EPS beat. Revenue has stabilized near $20B annually, but net margins are thin at 3.47%. The company is pivoting toward AI and cloud infrastructure, with recent news highlighting demand growth in these areas. Cash flow turned negative in 2025, though the balance sheet remains solid with $8.91B in cash.
Outlook is cautiously optimistic due to AI-driven demand and insider buying, but risks include telecom spending volatility and high P/E valuation. Analyst consensus is bullish with 60% buy ratings. The stock faces near-term pressure from technical indicators but offers long-term potential if AI initiatives accelerate growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
